Replimune Group Inc. shares cratered after the U.S. Food and Drug Administration delivered a second, definitive rejection of its lead skin cancer therapy, triggering an immediate corporate overhaul and sending investors into a panic. The stock plummeted roughly 30% on Friday to close at $4.76, slashing the company’s market value to approximately $393 million.
The FDA’s decision, communicated via a Complete Response Letter, centers on insufficient clinical data for the drug candidate RP1. The oncolytic immunotherapy is designed for use alongside nivolumab in advanced melanoma. Regulators specifically criticized the design of the pivotal IGNYTE trial, a single-arm Phase 1/2 study, stating it could not isolate RP1’s specific contribution to the combination’s efficacy. While the ongoing Phase 3 IGNYTE-3 study could address this, only about 10% of the planned patient population had been treated at the time of the FDA’s review.
In a sharp rebuke, Replimune’s CEO Sushil Patel contested the agency’s stance, arguing the regulatory system lacks flexibility for therapies targeting high unmet need rather than the drug itself having failed. He suggested the decision contradicted earlier signals from the FDA. Reports indicate leadership within the FDA’s oncology division played a key role in the stringent review. Notably, the agency had assigned a new review team for this second submission but arrived at the same conclusion, maintaining its clinical evidence requirements have been consistent since 2021.
Facing an existential threat to the RP1 program, management moved swiftly to enact severe cost-cutting measures. The company announced it will reduce its workforce and significantly scale back U.S. production capacities. The goal is to preserve capital while it re-evaluates the development pathway for RP1. These drastic steps were foreshadowed in recent SEC filings, which warned a second rejection could jeopardize the program’s future under the current corporate structure.
Should investors sell immediately? Or is it worth buying Replimune?
The financial picture adds intense pressure. As of December 31, 2025, Replimune held $269.1 million in cash and equivalents, a substantial decline from $483.8 million the prior year. While a recent amended credit agreement has pushed repayment obligations out to 2027, the company had previously cited an accelerated RP1 approval as necessary to advance the program. With that foundation gone, the preserved cash is now expected to fund operations only through the end of the first quarter of 2027.
Wall Street analysts are adjusting their outlooks in response. Cantor Fitzgerald downgraded the stock from “Overweight” to “Neutral.” Technically, the shares are deeply wounded, trading more than 20% below their 20-day moving average. The $4.70 level is now viewed as a critical technical support zone as trading resumes.
Investors await concrete details on the scope of the layoffs and the impact on research timelines. The company now faces a stark choice: pursue a formal dispute resolution process with the FDA or initiate new clinical studies to meet the regulatory bar. In the IGNYTE trial, the RP1 combination had demonstrated a 34% response rate with a median duration of response of 24.8 months, data that ultimately proved insufficient for the agency’s standards.
Ad
Replimune Stock: Buy or Sell?! New Replimune Analysis from April 12 delivers the answer:
The latest Replimune figures speak for themselves: Urgent action needed for Replimune investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from April 12.
Replimune: Buy or sell? Read more here...
